Catalyst Pharmaceuticals Future Growth
Future criteria checks 3/6
Catalyst Pharmaceuticals is forecast to grow earnings and revenue by 18.2% and 11.7% per annum respectively. EPS is expected to grow by 16.9% per annum. Return on equity is forecast to be 19.5% in 3 years.
Key information
18.2%
Earnings growth rate
16.9%
EPS growth rate
Biotechs earnings growth | 31.5% |
Revenue growth rate | 11.7% |
Future return on equity | 19.5% |
Analyst coverage | Good |
Last updated | 25 Apr 2024 |
Recent future growth updates
Recent updates
Earnings and Revenue Growth Forecasts
Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
---|---|---|---|---|---|
12/31/2026 | 628 | 207 | 245 | N/A | 5 |
12/31/2025 | 549 | 181 | 219 | 229 | 7 |
12/31/2024 | 461 | 135 | 169 | 189 | 7 |
12/31/2023 | 398 | 71 | -136 | 144 | N/A |
9/30/2023 | 348 | 62 | -114 | 128 | N/A |
6/30/2023 | 303 | 116 | -48 | 124 | N/A |
3/31/2023 | 256 | 99 | -53 | 120 | N/A |
12/31/2022 | 214 | 83 | 106 | 116 | N/A |
9/30/2022 | 192 | 67 | 85 | 95 | N/A |
6/30/2022 | 170 | 54 | 75 | 76 | N/A |
3/31/2022 | 154 | 45 | 65 | 65 | N/A |
12/31/2021 | 141 | 39 | 59 | 60 | N/A |
9/30/2021 | 134 | 42 | 53 | 54 | N/A |
6/30/2021 | 127 | 75 | 43 | 44 | N/A |
3/31/2021 | 120 | 72 | 41 | 42 | N/A |
12/31/2020 | 119 | 75 | 45 | 45 | N/A |
9/30/2020 | 118 | 71 | 44 | 44 | N/A |
6/30/2020 | 120 | 42 | 49 | 49 | N/A |
3/31/2020 | 119 | 43 | 50 | 50 | N/A |
12/31/2019 | 102 | 32 | 35 | 35 | N/A |
9/30/2019 | 73 | 9 | 14 | 14 | N/A |
6/30/2019 | 42 | -12 | -9 | -9 | N/A |
3/31/2019 | 13 | -29 | -28 | -28 | N/A |
12/31/2018 | 1 | -34 | -26 | -26 | N/A |
9/30/2018 | N/A | -25 | -22 | -22 | N/A |
6/30/2018 | N/A | -21 | -18 | -18 | N/A |
3/31/2018 | N/A | -19 | -16 | -16 | N/A |
12/31/2017 | N/A | -18 | -14 | -14 | N/A |
9/30/2017 | N/A | -17 | N/A | -14 | N/A |
6/30/2017 | N/A | -17 | N/A | -15 | N/A |
3/31/2017 | N/A | -18 | N/A | -16 | N/A |
12/31/2016 | N/A | -18 | N/A | -18 | N/A |
9/30/2016 | N/A | -20 | N/A | -18 | N/A |
6/30/2016 | N/A | -20 | N/A | -20 | N/A |
3/31/2016 | N/A | -20 | N/A | -20 | N/A |
12/31/2015 | N/A | -20 | N/A | -18 | N/A |
9/30/2015 | N/A | -18 | N/A | -17 | N/A |
6/30/2015 | N/A | -18 | N/A | -16 | N/A |
3/31/2015 | N/A | -17 | N/A | -14 | N/A |
12/31/2014 | N/A | -16 | N/A | -13 | N/A |
9/30/2014 | N/A | -13 | N/A | -13 | N/A |
6/30/2014 | N/A | -14 | N/A | -11 | N/A |
3/31/2014 | N/A | -14 | N/A | -10 | N/A |
12/31/2013 | N/A | -12 | N/A | -10 | N/A |
9/30/2013 | N/A | -11 | N/A | -7 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: CN2's forecast earnings growth (18.2% per year) is above the savings rate (0.7%).
Earnings vs Market: CN2's earnings (18.2% per year) are forecast to grow faster than the German market (15.4% per year).
High Growth Earnings: CN2's earnings are forecast to grow, but not significantly.
Revenue vs Market: CN2's revenue (11.7% per year) is forecast to grow faster than the German market (5.5% per year).
High Growth Revenue: CN2's revenue (11.7% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: CN2's Return on Equity is forecast to be low in 3 years time (19.5%).